Non-pharmacologic treatment strategies in gastroesophageal reflux disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue SUPPL. 3, 2004, Pages

  Sollano, Jose D ^a  

^a UNIVERSITY OF SANTO TOMAS   (Philippines)

Author keywords

Endoscopic therapy; Gastroesophageal reflux disease; Non pharmacological management; Surgery

Indexed keywords

CONFERENCE PAPER; DEVICE; DYSPHAGIA; ENDOSCOPIC THERAPY; GASTROESOPHAGEAL REFLUX; HUMAN; PLICATOR; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY RADIATION; SCORING SYSTEM; STOMACH FUNDOPLICATION; SUTURING METHOD; TREATMENT OUTCOME;

EID: 4544369553     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03593.x     Document Type: Conference Paper

References (43)

1. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux disease: Incidence and precipitating factors. Am. J. Dig Dis. 1976; 21: 953-6.
2. Locke GR, Talley NJ, Fett SL et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmstead County. Minnesota. Gasrroenterol. 1997; 112: 1448-56.
3. Eisen G. The Epidemiology of gastroesophageal reflux disease: what do we know and what we need to know. Am. J. Gastorenterol. 2001; 96: S16-8.
4. Sonnenberg A, El-Serag HB. Clinincal epidemiology and natural history of gastroesophageal reflux disease. Yale J. Biol. Med. 1999; 72: 81-92.
5. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand. J. Gastroenterol. Suppl. 1993; 199: 18-21.
6. Carlsson R, Watts R. et al. Gastro-esophageal reflux disease in primary care: an international study of different strategies with omeprazole. Eur J. Gastroenterol. Hepatol. 1998; 10: 119-24.
7. Ofman JJ. The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am. J. Gastroenterol. 2003; 98: S8-S14.
8. Levin TR, Schmittdiel JA, Kunz K, Henning JM et al. Costs of acid-related disorders to a health maintenance organization. Am. J. Med. 1997; 103: 520-8.
9. Ofman JJ, Dorn GH, Fennerty MB, Fass R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol. Ther. 2002; 16: 261-73.
10. Castell DO, Kharilas J, Ricther JE et al. Esomeprazole (40mg) compared with lansoprazole (30mg) in the treatment of erosive esophagitis. Am. J. Gastroenlerol. 2002; 97: 575-83.
11. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in Grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
12. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-esophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Library 2003, Issue 3, Oxford.
13. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton pump inhibitor lanzoprazole, rabeprazole and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized controlled trials. Clin. Ther 2001; 23: 998-1017.
14. Thjodleifsson B, Rindi G, Fiocca R. et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastroesophageal reflux disease over 5 years. Aliment Pharmacol. Ther. 2003; 17: 343-51.
15. Lind T, Havelund T, Carlsson R. et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand. J. Gastroenterol. 1997; 32: 974-9.
16. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am. J. Gastroenterol. 2002; 97: 1332-9.
17. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesopahgeal reflux disease patients. Am. J. Gastroenterol. 2003; 98: S31-9.
18. Bytzer P. On-demand therapy for gastroesophageal reflux disease. Eur J. Gastroenterol. Hepatol. 2001; 13: S19-22.
19. Wahlqvist P, Junghard D, Higgins A, Green J. Cost-effectiveness of proton pump inhibitors in gastro-esophageal reflux disease without esophagitis: comparison of on demand oesomeprazole with conventional omeprazole strategies. Pharmacoeconomics. 2002; 20: 267-77.
20. Katz PO. Review article. the role of non-acid reflux in gastro-esophageal reflux disease. Aliment Pharmacol. Ther. 2000; 14: 1539-51.
21. Xue S, Katz PO, Banerjee P, Castell DO. Bedtime H2blockers improve nocturnal gastric acid control in gastroesophageal reflux disease patients on PPI. Aliment Pharmacol. Ther. 2002; 15: 1351-6.
22. Kuipers E, Uyterlinde A, Pena AS et al. Long-term sequelae of Helicobacter associated gastritis. Lancet 1995; 345: 1525-8.
23. Galmiche JP, Zerbib F. Laparoscopic fundoplication is the treatment of choice for gastro-esophageal reflux disease. Gut 2002; 51: 472-4.
24. Fibbe C, Layer P, Keller J et al. Esophageal motility in reflux disease before and after fundoplication: a prospective, randomized, clinical, and manometric study. Gastroenterology 2001; 121: 5-14.
25. Bais JE, Bartelsman JF, Bonjer HJ et al. Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomized clinical trial. The Netherlands Antireflux Surgery Study Group. Lancet 2000; 355: 170-4.
26. Swanstrom L, Wayne R. Spectrum of gastrointestinal symptoms after laparoscopic fundoplication. Am. J. Surg. 1994; 167: 538-41.
27. Wo JM, Trus TL, Richardson WS et al. Evaluation and management of postfundoplication dysphagia. Am. J. Gastroenterol. 1996; 91: 2318-22.
28. Waring JP. Management of postfundoplication complications. Sem Gastrointest Dis. 1999; 10: 121-9.
29. Bammer T, Hinder RA, Klaus A, Klingler PJ. Five- to eight-year outcome of the first laparoscopic Nissen fundoplication. J. Gastrointest Surg. 2001; 5: 42-8.
30. Velanovich V, Ben-Menachem. T, Goel S. Case-control comparison of endoscopic gastroplication with laparoscopic fundoplication in the management of gastroesophageal reflux disease: early symptomatic outcomes. Surg. Laparosc. Endosc. Percutan. Tech. 2002; 12: 219-23.
31. Lundell L, Miettinen P, Myrvold HE et al. Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur. J. Gastroenterol. Hepatol. 2000; 12: 879-87.
32. Lundell L, Miettinen P, Myrvold HE et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J. Am. Coll Surg. 2001; 192: 172-9.
33. Spechler SJ, Lee E, Ahnen D et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331-8.
34. Galmiche JP, Bruley des Varannes S. Endoluminal therapies for gastro-oesophageal reflux disease. Lancet 2003; 361: 1119-21.
35. Johnson DA, Ganz R. Aisenberg J et al. Endoscopic, deep mural implantation of enteryx for the treatment of GERD. 6-month follow-up of a multicenter trial. Am. J. Gastroenterol. 2003; 98: 250-8.
36. Triadafilopoulos G, DiBaise JK, Nostrant TT et al. Radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD. Gastrointest. Endosc. 2001; 53: 407-15.
37. Corley DA, Katz P, Wo JM et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 2003; 125: 668-76.
38. Mahmood Z, McMahon BP, Arfin Q et al. Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up. Gut 2003; 52: 34-9.
39. Filipi CJ, Lehman GA, Rothstein RI et al. Transoral, flexible endoscopic suturing for treatment of GERD: a multicenter trial. Gastrointest. Endosc. 2001; 53: 416-22.
40. Chuttani R, Sud R, Sachdev G et al. A novel endoscopic full-thickness plicator for the treatment of GERD. A pilot study. Gastrointest. Endosc. 2003; 58: 770-6.
41. Vakil N, Sharma P. Review article: endoscopic treatments for gastroesophageal reflux disease. Aliment Pharmacol. Ther. 2003; 17: 1427-34.
42. Fennerty MB. Endoscopic therapy for gastroesophageal reflux disease: what have we learned and what needs to be done? Gastrointest. Endosc. Clin. N Am. 2003; 13: 201-9.
43. Quigley EM. Factors that influence therapeutic outcomes in symptomatic gastroesophageal reflux disease. Am. J. Gastroenterol. 2003; 98: S24-30.